Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542–56. https://doi.org/10.1016/j.jhep.2023.06.003.

Article  CAS  PubMed  Google Scholar 

Israelsen M, Francque S, Tsochatzis EA, Krag A. Steatotic liver disease. Lancet. 2024;404:1761–78. https://doi.org/10.1016/s0140-6736(24)01811-7.

Article  CAS  PubMed  Google Scholar 

Lim GEH, Tang A, Ng CH, Chin YH, Lim WH, Tan DJH, et al. An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD. Clin Gastroenterol Hepatol. 2023;21:619–29.e7. https://doi.org/10.1016/j.cgh.2021.11.038.

Huang DQ, Wong VWS, Rinella ME, Boursier J, Lazarus JV, Yki-Järvinen H, et al. Metabolic dysfunction-associated steatotic liver disease in adults. Nat Rev Dis Primers. 2025;11:14. https://doi.org/10.1038/s41572-025-00599-1.

Article  PubMed  Google Scholar 

Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21. https://doi.org/10.1002/hep.20701.

Article  PubMed  Google Scholar 

Pericàs JM, Anstee QM, Augustin S, Bataller R, Berzigotti A, Ciudin A, et al. A roadmap for clinical trials in MASH-related compensated cirrhosis. Nat Rev Gastroenterol Hepatol. 2024;21:809–23. https://doi.org/10.1038/s41575-024-00955-8.

Article  PubMed  Google Scholar 

Allen AM, Therneau TM, Ahmed OT, Gidener T, Mara KC, Larson JJ, et al. Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design. J Hepatol. 2022;77:1237–45. https://doi.org/10.1016/j.jhep.2022.07.004.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Souza M, Al-Sharif L, Diaz I, Khalil SM. Enrollment in metabolic dysfunction-associated steatohepatitis clinical trials: a pooled analysis of screen failure rates. Am J Gastroenterol. 2025. https://doi.org/10.14309/ajg.0000000000003520.

Article  PubMed  Google Scholar 

Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65:1557–65. https://doi.org/10.1002/hep.29085.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ratziu V, Francque S, Sanyal A. Breakthroughs in therapies for NASH and remaining challenges. J Hepatol. 2022;76:1263–78. https://doi.org/10.1016/j.jhep.2022.04.002.

Article  CAS  PubMed  Google Scholar 

Tacke F, Puengel T, Loomba R, Friedman SL. An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH. J Hepatol. 2023;79:552–66. https://doi.org/10.1016/j.jhep.2023.03.038.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brunt EM, Kleiner DE, Wilson LA, Sanyal AJ, Neuschwander-Tetri BA. Improvements in histologic features and diagnosis associated with improvement in fibrosis in nonalcoholic steatohepatitis: results from the Nonalcoholic Steatohepatitis Clinical Research Network treatment trials. Hepatology. 2019;70:522–31. https://doi.org/10.1002/hep.30418.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kleiner DE, Brunt EM, Wilson LA, Behling C, Guy C, Contos M, et al. Association of histologic disease activity with progression of nonalcoholic fatty liver disease. JAMA Netw Open. 2019;2:e1912565. https://doi.org/10.1001/jamanetworkopen.2019.12565.

Article  PubMed  PubMed Central  Google Scholar 

Francque S, Ratziu V. Future treatment options and regimens for nonalcoholic fatty liver disease. Clin Liver Dis. 2023;27:429–49. https://doi.org/10.1016/j.cld.2023.01.010.

Article  PubMed  Google Scholar 

Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389-97.e10. https://doi.org/10.1053/j.gastro.2015.04.043.

Article  PubMed  PubMed Central  Google Scholar 

Alkhouri N, Beyer C, Shumbayawonda E, Andersson A, Yale K, Rolph T, et al. Decreases in cT1 and liver fat content reflect treatment-induced histological improvements in MASH. J Hepatol. 2025;82:438–45. https://doi.org/10.1016/j.jhep.2024.08.031.

Article  CAS  PubMed  Google Scholar 

Cannella R, Matteini F, Gagliano DS, Mazzola M, Agnello F, Soresi M, et al. Performance of ultrasound liver fat quantification for the assessment of hepatic steatosis using MRI fat fraction as a reference standard. Ultrasound Med Biol. 2025;51:1495–502. https://doi.org/10.1016/j.ultrasmedbio.2025.05.020.

Article  PubMed  Google Scholar 

Park JH, Kim SM, Lee DH. Comparison of non-invasive methods for diagnosis of non-alcoholic fatty liver disease before bariatric surgery and postoperative follow-up in obese patients. J Metab Bariatr Surg. 2025;14:53–64. https://doi.org/10.17476/jmbs.2025.14.1.53.

Article  PubMed  PubMed Central  Google Scholar 

Malandris K, Katsoula A, Liakos A, Bekiari E, Karagiannis T, Theocharidou E, et al. Accuracy of controlled attenuation parameter for liver steatosis in patients at risk for metabolic dysfunction-associated steatotic liver disease using magnetic resonance imaging: a systematic review and meta-analysis. Ann Gastroenterol. 2024;37:579–87. https://doi.org/10.20524/aog.2024.0910.

Article  PubMed  PubMed Central  Google Scholar 

Malandris K, Korakas E, Sarakapina A, Kalopitas G, Iatridi F, Liakos A, et al. Accuracy of controlled attenuation parameter for liver steatosis in high-risk patients for MASLD using MRI-proton density fat fraction as reference standard. Dig Dis Sci. 2025;70:814–24. https://doi.org/10.1007/s10620-024-08799-7.

Article  CAS  PubMed  Google Scholar 

Petroff D, Blank V, Newsome PN, Shalimar, Voican CS, Thiele M, et al. Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. Lancet Gastroenterol Hepatol. 2021;6:185–98. https://doi.org/10.1016/s2468-1253(20)30357-5

Ferraioli G. CAP for the detection of hepatic steatosis in clinical practice. Lancet Gastroenterol Hepatol. 2021;6:151–2. https://doi.org/10.1016/s2468-1253(20)30367-8.

Article  PubMed  Google Scholar 

Krahmer N, Walther TC, Farese RV Jr. The pathogenesis of hepatic steatosis in MASLD: a lipid droplet perspective. J Clin Invest. 2025. https://doi.org/10.1172/jci198334.

Article  PubMed  PubMed Central  Google Scholar 

Steinberg GR, Carpentier AC, Wang D. MASH: the nexus of metabolism, inflammation, and fibrosis. J Clin Invest. 2025. https://doi.org/10.1172/jci186420.

Article  PubMed  PubMed Central  Google Scholar 

Gastaldelli A, Cusi K. From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options. JHEP Rep. 2019;1:312–28. https://doi.org/10.1016/j.jhepr.2019.07.002.

Article  PubMed  PubMed Central  Google Scholar 

Lambert JE, Ramos-Roman MA, Valdez MJ, Browning JD, Rogers T, Parks EJ. Weight loss in MASLD restores the balance of liver fatty acid sources. J Clin Invest. 2025. https://doi.org/10.1172/jci174233.

Article  PubMed  PubMed Central  Google Scholar 

Liu WY, Huang S, Ji H, Kim SU, Yip TC, Wong GL, et al. From ‘burnt-out’ to ‘burning-out’: capturing liver fat loss in patients with advanced metabolic dysfunction-associated steatotic liver disease from a dynamic perspective. Gastroenterology. 2025;169:326-336.e4. https://doi.org/10.1053/j.gastro.2025.02.034.

Article  CAS  PubMed  Google Scholar 

Bedossa P. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology. 2014;60:565–75. https://doi.org/10.1002/hep.27173.

Article  CAS  PubMed  Google Scholar 

Abdurrachim D, Lek S, Ong CZL, Wong CK, Zhou Y, Wee A, et al. Utility of AI digital pathology as an aid for pathologists scoring fibrosis in MASH. J Hepatol. 2025;82:898–908. https://doi.org/10.1016/j.jhep.2024.11.032.

Article  CAS  PubMed